{"transactions":[{"id":978176,"issuer":{"id":5072,"kind":"organization","name":"ACHIEVE LIFE SCIENCES, INC.","symbol":"ACHV"},"owners":[{"id":72115,"kind":"person","name":"Atkisson Erik","position":1,"cik":"0001885915","reported_name":"Atkisson Erik","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-12-08T21:01:03.000Z","date":"2025-12-04","kind":"grant","planned":false,"acquired":true,"shares":250000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option will vest as to 1/4 of the total award on the first anniversary of October 20, 2025, and thereafter in substantially equal monthly installments over 36 months, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":250000,"derivative":{"exercise_price":4.78,"expiration_date":"2035-12-04","underlying":"Common Stock","underlying_shares":250000},"source":{"system":"sec-edgar","filing":"0001193125-25-311199","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/949858/000119312525311199/ownership.xml","form_type":"4"}},{"id":1669800,"issuer":{"id":94695,"kind":"organization","name":"Rain Oncology Inc.","symbol":"RAIN"},"owners":[{"id":72115,"kind":"person","name":"Atkisson Erik","position":1,"cik":"0001885915","reported_name":"Atkisson Erik","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel and CCO"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-01-26T16:38:10.000Z","date":"2024-01-26","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":60251,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Merger Agreement entered into by and among the Issuer, Pathos AI, Inc. (\"Parent\") and WK Merger Sub, Inc., a wholly owned subsidiary of Parent (\"Merger Sub\"), dated as of December 13, 2023 (the \"Merger Agreement\"), pursuant to which Merger Sub completed a tender offer for all of the shares of common stock of the Issuer (each, a \"Share\") and thereafter merged with and into the Issuer effective as of January 26, 2024 (the \"Effective Time\"). Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under the Issuer's Amended and Restated 2018 Stock Option/Stock Issuance Plan or the Issuer's 2021 Equity Incentive Plan, pursuant to any inducement award or otherwise that was outstanding immediately prior to the Effective Time was cancelled for no consideration."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Merger Agreement entered into by and among the Issuer, Pathos AI, Inc. (\"Parent\") and WK Merger Sub, Inc., a wholly owned subsidiary of Parent (\"Merger Sub\"), dated as of December 13, 2023 (the \"Merger Agreement\"), pursuant to which Merger Sub completed a tender offer for all of the shares of common stock of the Issuer (each, a \"Share\") and thereafter merged with and into the Issuer effective as of January 26, 2024 (the \"Effective Time\"). Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under the Issuer's Amended and Restated 2018 Stock Option/Stock Issuance Plan or the Issuer's 2021 Equity Incentive Plan, pursuant to any inducement award or otherwise that was outstanding immediately prior to the Effective Time was cancelled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Merger Agreement entered into by and among the Issuer, Pathos AI, Inc. (\"Parent\") and WK Merger Sub, Inc., a wholly owned subsidiary of Parent (\"Merger Sub\"), dated as of December 13, 2023 (the \"Merger Agreement\"), pursuant to which Merger Sub completed a tender offer for all of the shares of common stock of the Issuer (each, a \"Share\") and thereafter merged with and into the Issuer effective as of January 26, 2024 (the \"Effective Time\"). Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under the Issuer's Amended and Restated 2018 Stock Option/Stock Issuance Plan or the Issuer's 2021 Equity Incentive Plan, pursuant to any inducement award or otherwise that was outstanding immediately prior to the Effective Time was cancelled for no consideration."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Merger Agreement entered into by and among the Issuer, Pathos AI, Inc. (\"Parent\") and WK Merger Sub, Inc., a wholly owned subsidiary of Parent (\"Merger Sub\"), dated as of December 13, 2023 (the \"Merger Agreement\"), pursuant to which Merger Sub completed a tender offer for all of the shares of common stock of the Issuer (each, a \"Share\") and thereafter merged with and into the Issuer effective as of January 26, 2024 (the \"Effective Time\"). Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under the Issuer's Amended and Restated 2018 Stock Option/Stock Issuance Plan or the Issuer's 2021 Equity Incentive Plan, pursuant to any inducement award or otherwise that was outstanding immediately prior to the Effective Time was cancelled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":1.21,"underlying":"Common Stock","underlying_shares":60251},"source":{"system":"sec-edgar","filing":"0001999371-24-000960","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1885915/000199937124000960/ownership.xml","form_type":"4"}},{"id":1669799,"issuer":{"id":94695,"kind":"organization","name":"Rain Oncology Inc.","symbol":"RAIN"},"owners":[{"id":72115,"kind":"person","name":"Atkisson Erik","position":1,"cik":"0001885915","reported_name":"Atkisson Erik","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel and CCO"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-01-26T16:38:10.000Z","date":"2024-01-26","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":82882,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Merger Agreement entered into by and among the Issuer, Pathos AI, Inc. (\"Parent\") and WK Merger Sub, Inc., a wholly owned subsidiary of Parent (\"Merger Sub\"), dated as of December 13, 2023 (the \"Merger Agreement\"), pursuant to which Merger Sub completed a tender offer for all of the shares of common stock of the Issuer (each, a \"Share\") and thereafter merged with and into the Issuer effective as of January 26, 2024 (the \"Effective Time\"). Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under the Issuer's Amended and Restated 2018 Stock Option/Stock Issuance Plan or the Issuer's 2021 Equity Incentive Plan, pursuant to any inducement award or otherwise that was outstanding immediately prior to the Effective Time was cancelled for no consideration."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Merger Agreement entered into by and among the Issuer, Pathos AI, Inc. (\"Parent\") and WK Merger Sub, Inc., a wholly owned subsidiary of Parent (\"Merger Sub\"), dated as of December 13, 2023 (the \"Merger Agreement\"), pursuant to which Merger Sub completed a tender offer for all of the shares of common stock of the Issuer (each, a \"Share\") and thereafter merged with and into the Issuer effective as of January 26, 2024 (the \"Effective Time\"). Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under the Issuer's Amended and Restated 2018 Stock Option/Stock Issuance Plan or the Issuer's 2021 Equity Incentive Plan, pursuant to any inducement award or otherwise that was outstanding immediately prior to the Effective Time was cancelled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Merger Agreement entered into by and among the Issuer, Pathos AI, Inc. (\"Parent\") and WK Merger Sub, Inc., a wholly owned subsidiary of Parent (\"Merger Sub\"), dated as of December 13, 2023 (the \"Merger Agreement\"), pursuant to which Merger Sub completed a tender offer for all of the shares of common stock of the Issuer (each, a \"Share\") and thereafter merged with and into the Issuer effective as of January 26, 2024 (the \"Effective Time\"). Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under the Issuer's Amended and Restated 2018 Stock Option/Stock Issuance Plan or the Issuer's 2021 Equity Incentive Plan, pursuant to any inducement award or otherwise that was outstanding immediately prior to the Effective Time was cancelled for no consideration."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Merger Agreement entered into by and among the Issuer, Pathos AI, Inc. (\"Parent\") and WK Merger Sub, Inc., a wholly owned subsidiary of Parent (\"Merger Sub\"), dated as of December 13, 2023 (the \"Merger Agreement\"), pursuant to which Merger Sub completed a tender offer for all of the shares of common stock of the Issuer (each, a \"Share\") and thereafter merged with and into the Issuer effective as of January 26, 2024 (the \"Effective Time\"). Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under the Issuer's Amended and Restated 2018 Stock Option/Stock Issuance Plan or the Issuer's 2021 Equity Incentive Plan, pursuant to any inducement award or otherwise that was outstanding immediately prior to the Effective Time was cancelled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":9.34,"underlying":"Common Stock","underlying_shares":82882},"source":{"system":"sec-edgar","filing":"0001999371-24-000960","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1885915/000199937124000960/ownership.xml","form_type":"4"}},{"id":1669798,"issuer":{"id":94695,"kind":"organization","name":"Rain Oncology Inc.","symbol":"RAIN"},"owners":[{"id":72115,"kind":"person","name":"Atkisson Erik","position":1,"cik":"0001885915","reported_name":"Atkisson Erik","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel and CCO"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-01-26T16:38:10.000Z","date":"2024-01-26","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":37118,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Merger Agreement entered into by and among the Issuer, Pathos AI, Inc. (\"Parent\") and WK Merger Sub, Inc., a wholly owned subsidiary of Parent (\"Merger Sub\"), dated as of December 13, 2023 (the \"Merger Agreement\"), pursuant to which Merger Sub completed a tender offer for all of the shares of common stock of the Issuer (each, a \"Share\") and thereafter merged with and into the Issuer effective as of January 26, 2024 (the \"Effective Time\"). Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under the Issuer's Amended and Restated 2018 Stock Option/Stock Issuance Plan or the Issuer's 2021 Equity Incentive Plan, pursuant to any inducement award or otherwise that was outstanding immediately prior to the Effective Time was cancelled for no consideration."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Merger Agreement entered into by and among the Issuer, Pathos AI, Inc. (\"Parent\") and WK Merger Sub, Inc., a wholly owned subsidiary of Parent (\"Merger Sub\"), dated as of December 13, 2023 (the \"Merger Agreement\"), pursuant to which Merger Sub completed a tender offer for all of the shares of common stock of the Issuer (each, a \"Share\") and thereafter merged with and into the Issuer effective as of January 26, 2024 (the \"Effective Time\"). Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under the Issuer's Amended and Restated 2018 Stock Option/Stock Issuance Plan or the Issuer's 2021 Equity Incentive Plan, pursuant to any inducement award or otherwise that was outstanding immediately prior to the Effective Time was cancelled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Merger Agreement entered into by and among the Issuer, Pathos AI, Inc. (\"Parent\") and WK Merger Sub, Inc., a wholly owned subsidiary of Parent (\"Merger Sub\"), dated as of December 13, 2023 (the \"Merger Agreement\"), pursuant to which Merger Sub completed a tender offer for all of the shares of common stock of the Issuer (each, a \"Share\") and thereafter merged with and into the Issuer effective as of January 26, 2024 (the \"Effective Time\"). Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under the Issuer's Amended and Restated 2018 Stock Option/Stock Issuance Plan or the Issuer's 2021 Equity Incentive Plan, pursuant to any inducement award or otherwise that was outstanding immediately prior to the Effective Time was cancelled for no consideration."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Merger Agreement entered into by and among the Issuer, Pathos AI, Inc. (\"Parent\") and WK Merger Sub, Inc., a wholly owned subsidiary of Parent (\"Merger Sub\"), dated as of December 13, 2023 (the \"Merger Agreement\"), pursuant to which Merger Sub completed a tender offer for all of the shares of common stock of the Issuer (each, a \"Share\") and thereafter merged with and into the Issuer effective as of January 26, 2024 (the \"Effective Time\"). Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under the Issuer's Amended and Restated 2018 Stock Option/Stock Issuance Plan or the Issuer's 2021 Equity Incentive Plan, pursuant to any inducement award or otherwise that was outstanding immediately prior to the Effective Time was cancelled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":9.34,"underlying":"Common Stock","underlying_shares":37118},"source":{"system":"sec-edgar","filing":"0001999371-24-000960","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1885915/000199937124000960/ownership.xml","form_type":"4"}},{"id":1810052,"issuer":{"id":94695,"kind":"organization","name":"Rain Oncology Inc.","symbol":"RAIN"},"owners":[{"id":72115,"kind":"person","name":"Atkisson Erik","position":1,"cik":"0001885915","reported_name":"Atkisson Erik","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel and CCO"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-08-11T21:04:00.000Z","date":"2023-08-09","kind":"grant","planned":false,"acquired":true,"shares":60251,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase a total of 60,251 shares of the Issuer's common stock, one half of which will vest on May 9, 2024, with the remaining one half vesting in full on February 9, 2025, subject to the Reporting Person's continued service to the Issuer."}],"balance_after":60251,"derivative":{"exercise_price":1.21,"expiration_date":"2033-08-09","underlying":"Common Stock","underlying_shares":60251},"source":{"system":"sec-edgar","filing":"0001104659-23-090696","document":"tm2323614-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1885915/000110465923090696/tm2323614-2_4seq1.xml","form_type":"4"}},{"id":1974755,"issuer":{"id":94695,"kind":"organization","name":"Rain Oncology Inc.","symbol":"RAIN"},"owners":[{"id":72115,"kind":"person","name":"Atkisson Erik","position":1,"cik":"0001885915","reported_name":"Atkisson Erik","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel and CCO"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-03-03T17:07:20.000Z","date":"2023-03-02","kind":"grant","acquired":true,"shares":120000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase a total of 120,000 shares of the Issuer's common stock, one quarter of which will vest on February 21, 2024, with the remaining three quarters vesting in equal monthly installments through February 21, 2027, subject to the Reporting Person's continued service to the Issuer."}],"balance_after":120000,"derivative":{"exercise_price":9.34,"expiration_date":"2033-03-02","underlying":"Common Stock","underlying_shares":120000},"source":{"system":"sec-edgar","filing":"0001104659-23-028498","document":"tm238527-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1885915/000110465923028498/tm238527-2_4seq1.xml","form_type":"4"}},{"id":2042377,"issuer":{"id":16554,"kind":"organization","name":"Eiger BioPharmaceuticals, Inc.","symbol":"EIGR"},"owners":[{"id":72115,"kind":"person","name":"Atkisson Erik","position":1,"cik":"0001885915","reported_name":"Atkisson Erik","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"GC & Chief Compliance Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-01-30T21:15:13.000Z","date":"2023-01-26","kind":"grant","acquired":true,"shares":26750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 50% on the first anniversary of the January 26, 2023 grant date, and as to the remaining 50% on June 26, 2024, subject to the Reporting Person's continuous service as of each such date.  The option vests in full upon a change in control of the Issuer."}],"balance_after":26750,"derivative":{"exercise_price":1.37,"expiration_date":"2033-01-26","underlying":"Common Stock","underlying_shares":26750},"source":{"system":"sec-edgar","filing":"0001567619-23-001473","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1885915/000156761923001473/doc1.xml","form_type":"4"}},{"id":2337966,"issuer":{"id":16554,"kind":"organization","name":"Eiger BioPharmaceuticals, Inc.","symbol":"EIGR"},"owners":[{"id":72115,"kind":"person","name":"Atkisson Erik","position":1,"cik":"0001885915","reported_name":"Atkisson Erik","relationship":{"officer":true,"officer_title":"GC & Chief Compliance Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-03-11T21:06:17.000Z","date":"2022-03-11","kind":"grant","acquired":true,"shares":38000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vests in 48 equal monthly installments commencing on the grant date of March 11, 2022, subject to the Reporting Person's continuous service as of such date."}],"balance_after":38000,"derivative":{"exercise_price":5.1,"expiration_date":"2032-03-10","underlying":"Common Stock","underlying_shares":38000},"source":{"system":"sec-edgar","filing":"0001140361-22-009255","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1885915/000114036122009255/form4.xml","form_type":"4"}},{"id":2337965,"issuer":{"id":16554,"kind":"organization","name":"Eiger BioPharmaceuticals, Inc.","symbol":"EIGR"},"owners":[{"id":72115,"kind":"person","name":"Atkisson Erik","position":1,"cik":"0001885915","reported_name":"Atkisson Erik","relationship":{"officer":true,"officer_title":"GC & Chief Compliance Officer"}}],"security":"Common Stock","published_at":"2022-03-11T21:06:17.000Z","date":"2022-03-11","kind":"grant","acquired":true,"shares":6000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares underlying Restricted Stock Units award that will vest as to 33.3% on each of the first, second and third anniversaries of the grant date of March 11, 2022."}],"balance_after":6000,"source":{"system":"sec-edgar","filing":"0001140361-22-009255","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1885915/000114036122009255/form4.xml","form_type":"4"}},{"id":2554720,"issuer":{"id":16554,"kind":"organization","name":"Eiger BioPharmaceuticals, Inc.","symbol":"EIGR"},"owners":[{"id":72115,"kind":"person","name":"Atkisson Erik","position":1,"cik":"0001885915","reported_name":"Atkisson Erik","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"GC & Chief Compliance Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-10-01T16:35:28.000Z","date":"2021-09-30","kind":"grant","acquired":true,"shares":180000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as follows: 25% of the shares subject to the option shall vest on the one-year anniversary of the vesting commencement date of September 20, 2021, with the remaining shares to vest in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service as of each such date."}],"balance_after":180000,"derivative":{"exercise_price":6.68,"expiration_date":"2031-09-29","underlying":"Common Stock","underlying_shares":180000},"source":{"system":"sec-edgar","filing":"0001567619-21-017752","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1885915/000156761921017752/doc1.xml","form_type":"4"}}]}